Prescriptions
Buyers don’t want more options; they want guided clarity.
The modern buying environment is crowded, cross‑functional, and risk‑sensitive. Buying groups average ~13 stakeholders, 89% of decisions cross departments, and 86% of purchases stall at some point—classic signs of decision fatigue and ambiguity inside committees. That is why “presenting options” often extends, rather than shortens, cycles. Sellers who diagnose precisely and recommend credibly help buyers reach alignment faster. (Forrester: The State of Business Buying, 2024
Omnichannel complexity compounds the problem. B2B buyers now use about ten interaction channels on average and more than half will switch suppliers if the experience across those channels is clumsy. A clear prescription that survives movement between email, Slack, internal docs, steering‑committee decks, and procurement templates reduces friction and makes the path to “yes” easier to carry. (McKinsey B2B Pulse 2024
What it means: Buyers don’t need another slide of choices. They need a defensible recommendation tied to their goals, expressed in their language, and easy to repeat internally.
Ambiguity is now a deal‑killer
Across pipeline reviews, the stalling pattern looks similar:
Buyers ask for “one more” demo, reference, or deck because no one has anchored a decision.
Champions struggle to articulate a recommended path for the room that actually decides.
Committees circulate options without a crisp rationale, then default to delay.
These symptoms are predictable in late‑stage evaluations. In software, the CFO frequently holds final decision power (79%) and Legal slows or blocks 61% of purchases. If your guidance is vague, finance cannot validate the case and legal cannot approve with confidence. ([G2 Buyer Behavior 2024, Business Wire summary]
Meanwhile, buyers are ~70% through their journey before engaging sales, and 81% already have a preferred vendor at first contact. If you’re not the early favorite, your edge is not “neutrality”; it’s a recommendation that reframes the choice with evidence and a clear rationale. (6sense 2024
Buyers don’t resist direction—they resist pressure
Most reps avoid recommending because they fear sounding pushy. Yet internal analyses and buyer research point to a different root cause of resistance: missing rationale. Buyers accept direction when three conditions hold:
Accurate diagnosis. They feel seen and understood.
Transparent logic. The “why this, not that” is explicit.
Preserved autonomy. The choice feels like theirs, not yours.
This matches what late‑stage committees reward: defensibility. A recommendation anchored in the buyer’s KPIs and risk posture plays well in CFO/Legal reviews and across the ~10 channels information travels. (McKinsey B2B Pulse 2024; [G2 2024]
Why prescription selling works (the “trusted advisor” effect)
Think about how a physician advises:
They start with a thorough diagnosis, not generic symptoms.
They explain trade‑offs and risks plainly.
They recommend with authority, yet respect the patient’s choice.
They define concrete next steps that reduce anxiety.
In B2B, this reduces committee friction and decision fatigue. It also increases the odds that your champion can repeat your reasoning—nearly verbatim—in the meeting you won’t attend.
A practical framework: recommend without sounding pushy (5 parts)
Use this structure to deliver prescriptions that feel earned, not imposed.
1) Open with a precise diagnosis
Synthesize what you’ve heard into a one‑to‑two sentence assessment grounded in observable evidence.
“From what you’ve shared—slow approvals, inconsistent data, and rising workload—the constraint isn’t your core system; it’s the hand‑offs and criteria gaps between teams using it.”
Why it works: Diagnosis earns the right to recommend and signals neutrality to broader committees that crave defensibility (CFO/Legal). ([G2 2024]
2) Name the core objective before your solution
State their goal in their words.
“Your goal is to reduce cycle time without adding headcount or increasing audit risk.”
Why it works: Anchoring to their KPI aligns with the way large groups decide and with finance’s expectation for clarity. (Forrester 2024
3) Recommend with conditional language
Assertive, not coercive:
“Based on what we discussed, the path most aligned is…”
“If your priority is X, the most effective step would be…”
Why it works: Conditional phrasing preserves autonomy while providing direction, crucial in omnichannel environments where messages will be forwarded and re‑read. (McKinsey 2024
4) Explain the rationale (the “why this, not that”)
Articulate how the approach resolves root causes and reduces risk:
“This approach removes the approval bottleneck and eliminates manual rework. It also narrows dependencies, which lowers slippage risk during finance and legal review.”
Why it works: CFO and Legal need the “why” to validate value and risk posture; 79% CFO final‑say and 61% legal friction make rationale non‑negotiable. ([G2 2024]
5) Offer a credible alternative—and explain its trade‑offs
Reinforce neutrality by acknowledging another route:
“An incremental path is possible, but given your growth targets, it likely prolongs the bottleneck and adds change‑management overhead.”
Why it works: Presenting an alternative communicates stewardship, not quota‑driven bias. It arms your champion for the inevitable “why not option B?” question.
Make your prescription travel‑ready (so champions can carry it internally)
A recommendation that closes must survive the room you won’t be in. Package it so people can copy/paste with confidence:
One‑line diagnosis of the constraint.
Buyer‑stated objective tied to KPIs (cycle time, error rate, time‑to‑value).
Recommended path + conditional phrasing.
Three‑point rationale (root causes addressed, dependencies reduced, risk posture improved).
One alternative + trade‑off.
This is the simplest form of “champion enablement”—and it’s built for committees spanning ~10 channels. (McKinsey 2024
What great prescriptions look like (two quick templates)
Template A — Ops acceleration
Diagnosis: “Your delays stem from cross‑team approvals and inconsistent criteria, not tool limits.”
Objective: “Reduce cycle time 25% without adding headcount.”
Recommendation: “If that’s the goal, the best path is standardized approval gates with role‑based criteria and automated checks.”
Rationale: “Removes hand‑off variance, cuts rework, and clarifies audit trails for finance/legal.”
Alternative: “Incremental tweaks keep flexibility but likely extend delay through Q3.”
Template B — Risk & governance
Diagnosis: “Security objections arise from missing audit logs across two systems.”
Objective: “Pass legal review without extending close timelines.”
Recommendation: “Adopt centralized logging and pre‑built controls in Phase 1; defer optional integrations to Phase 2.”
Rationale: “Addresses legal concerns now, contains scope, minimizes slippage.”
Alternative: “A full re‑platform is possible but extends decision latency and raises cost of delay.”
Each template speaks fluently to CFO/Legal gatekeepers and accounts for the stall risk common in multi‑stakeholder deals. (Forrester 2024; [G2 2024]
Business impact: why prescription selling raises win rates
Higher win rates. Direction reduces uncertainty and helps committees converge; in high‑scrutiny cycles, clarity beats optionality. ([Forrester 2024]( [learn.g2.com]
Faster cycles. Recommendations act as alignment devices across ~13 stakeholders and ~10 channels, cutting circular debate. ([Forrester 2024](; McKinsey 2024 [learn.g2.com]
Fewer no‑decisions. Strong prescriptions de‑risk the choice for CFO and Legal, who commonly slow or block deals. ([G2 2024]
Stronger champion enablement. A travel‑ready rationale is easy to repeat and defend.
Actionable takeaways (for your next call)
Earn the right: lead with a crisp diagnosis of root causes. (Forrester 2024
Anchor to their KPI before you mention your solution.
Recommend with conditional phrasing to keep autonomy intact. (McKinsey 2024
Spell out the rationale in three bullet points that CFO/Legal will accept. ([G2 2024]
Offer one alternative and its trade‑offs to signal neutrality.
Package the prescription so your champion can copy/paste it into the next internal deck.
Buyers don’t resist recommendations; they resist unearned recommendations. Prescription selling works because it delivers clarity, reduces risk, and respects autonomy—the exact conditions late‑stage B2B buyers trust the most.
